ABT - Company ID 0000001800
ABBOTT LABORATORIES (ABT) reported net income of $6.52B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $6.52B | -51.3% |
| FY 2024 | $13.40B | +134.2% |
| FY 2023 | $5.72B | -17.5% |
| FY 2022 | $6.93B | -2.0% |
| FY 2021 | $7.07B | +57.3% |
| FY 2020 | $4.50B | +21.9% |
| FY 2019 | $3.69B | +55.7% |
| FY 2018 | $2.37B | +396.4% |
| FY 2017 |
ABBOTT LABORATORIES (ABT) reported net income of $6.52B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ABBOTT LABORATORIES's net income grew from $4.73B to $6.52B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $477.00M |
| -65.9% |
| FY 2016 | $1.40B | -68.3% |
| FY 2015 | $4.42B | +93.7% |
| FY 2014 | $2.28B | -11.3% |
| FY 2013 | $2.58B | -56.8% |
| FY 2012 | $5.96B | +26.1% |
| FY 2011 | $4.73B | - |